Evozyne to develop synthetic proteins for Takeda gene therapies

By The Science Advisory Board staff writers

Molecular engineering company Evozyne has signed a strategic collaboration and license agreement with Takeda Pharmaceutical. The partnership's aim is to develop proteins that can be incorporated into next-generation gene therapies for genetic disorders within inborn errors of metabolism and lysosomal storage diseases.

Evozyne uses advanced computational and machine-learning methods in its evolution-based engineering process to create synthetic proteins with precision and efficiency. In partnership with Takeda, Evozyne will create novel protein sequences for gene therapies. At completion, Takeda will have the option to obtain an exclusive license to develop and commercialize the novel protein sequences as part of its gene therapy program.

Under the agreement, Evozyne is eligible to receive an upfront payment of an undisclosed amount and additional research, development, and regulatory milestone payments, as well as royalties on sales of any commercial products resulting from the collaboration.

Copyright © 2021 scienceboard.net

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?